VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) added to NASDAQ Biotechnology Index

12/20/2021 | 12:00am EDT

Viracta Therapeutics, Inc. has been added to NASDAQ Biotechnology Index.


© S&P Capital IQ 2021
All news about VIRACTA THERAPEUTICS, INC.
05/13Viracta Therapeutics Announces New Employment Inducement Grant
PR
05/11Viracta Therapeutics to Present at Upcoming May Investor Conferences
PR
05/10SUNESIS : Q1 Earnings Snapshot
AQ
05/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
PR
04/27VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27TRANSCRIPT : Viracta Therapeutics, Inc. - Special Call
CI
04/20Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment o..
PR
04/15VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/15Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election A..
CI
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -47,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,77x
Yield 2022 -
Capitalization 77,6 M 77,6 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 28
Free-Float 60,7%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,07 $
Average target price 20,00 $
Spread / Average Target 866%
EPS Revisions
Managers and Directors
Ivor Royston Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Director
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-43.29%76
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524